Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous mesenchymal stem cells for refractory Crohn's disease
NL-OMON22654Phase 1Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2008
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous mesenchymal stem cells in Crohn's disease, sponsored by Leiden University Medical Center. Primary endpoints: Safety and Feasibility. Started Jan 2008; status: active, not recruiting.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON22654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22654.